PLGA from PolySciTech : Akina used in development of hydrogel for treatment of heart disease

 

Heart disease is the main cause of death worldwide. Researchers at University of Texas at Arlington and The University of Akron used PLGA (cat# AP154) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop SDF-1a releasing particles to load in with hydrogel matrix to repair damaged heart tissue. This research holds promise to improve treatments against heart-attacks and related cardiovascular diseases. Rear more: Xu, Jiazhu, Jacob Brown, Rubia Shaik, Luis Soto-Garcia, Jun Liao, Kytai Nguyen, Ge Zhang, and Yi Hong. "Injectable myocardium-derived hydrogels with SDF-1α releasing for cardiac repair." Biomaterials Advances (2025): 214203. https://www.sciencedirect.com/science/article/pii/S2772950825000305

“Developed a nanocomposite hydrogel by encapsulating SDF-1α-loaded PLGA NPs into a cdECM hydrogel. Achieved sustained SDF-1α release over four weeks in vitro, compared to one week for direct encapsulation. PLGA NPs incorporation enhanced cdECM hydrogel mechanics, significantly improving both stiffness and strength. Demonstrated the ability to accelerate angiogenesis and restore cardiac function in a rat MI model. Myocardial infarction (MI) is a predominant cause of morbidity and mortality globally. Therapeutic chemokines, such as stromal cell-derived factor 1α (SDF-1α), present a promising opportunity to treat the profibrotic remodeling post-MI if they can be delivered effectively to the injured tissue. However, direct injection of SDF-1α or physical entrapment in a hydrogel has shown limited efficacy. Here, we developed a sustained-release system consisting of SDF-1α loaded poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) and an injectable porcine cardiac decellularized extracellular matrix (cdECM) hydrogel. This system demonstrated a sustained release of SDF-1α over four weeks while there is one week release for SDF-1α directly encapsulated in the cdECM hydrogel during in vitro testing. The incorporation of PLGA NPs into the cdECM hydrogel significantly enhanced its mechanical properties, increasing the Young's modulus from 561 ± 228 kPa to 1007 ± 2 kPa and the maximum compressive strength from 639 ± 42 kPa to 1014 ± 101 kPa. This nanocomposite hydrogel showed good cell compatibility after 7 days of culture with H9C2 cells, while the released SDF-1α retained its bioactivity, as evidenced by its chemotactic effects in vitro. Furthermore, in vivo studies further highlighted its significant ability to promote angiogenesis in the infarcted area and improve cardiac function after intramyocardial injection. These results demonstrated the therapeutic potential of combining local release of SDF-1α with the cdECM hydrogel for MI treatment.”

PLGA (Cat# AP154): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP154#h

Akina, Inc. launches new GMP manufacturing service available to outside customers https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/